Skip to main content
Genexine, Inc. logo

Genexine, Inc. — Investor Relations & Filings

Ticker · 095700 ISIN · KR7095700001 KO Manufacturing
Open in API
Filings indexed 342 across all filing types
Latest filing 2026-06-04 Regulatory Filings
Country KR South Korea
Listing KO 095700

About Genexine, Inc.

http://www.genexine.com/

Genexine, Inc. is a clinical-stage biotechnology company focused on developing and commercializing immunotherapeutics and next-generation biologics. The company utilizes its proprietary hyFc® platform technology to create long-acting protein therapeutics. Its pipeline is led by GX-I7, a long-acting interleukin-7 designed to amplify T-cell counts for immuno-oncology applications. Other key assets in late-stage clinical trials include GX-E4, a long-acting treatment for anemia, and GX-H9 for growth hormone deficiency. Genexine's research and development efforts primarily target oncology and rare diseases.

Recent filings

Filing Released Lang Actions
투자판단관련주요경영사항 (에페사프리필드시린지주(GX-E4) 한국 품목허가 신청결과)
Regulatory Filings Classification · 89% confidence The document is a regulatory disclosure of a significant management event (“투자판단 관련 주요경영사항”) under Korean securities rules, announcing the Korea MFDS’s rejection of a drug approval application. It is an event announcement rather than a financial report, earnings release, or management change notice, and does not fit any specific category such as dividends, M&A, or interim report. Therefore, it falls under general regulatory announcements (RNS).
2026-06-04 Korean
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 93% confidence The document is titled “분기보고서” (Quarterly Report) covering the 28th fiscal year Q1 (2026-01-01 to 2026-03-31). It contains detailed corporate overview, business description, complete financial statements (consolidated and separate), management discussion & analysis, auditor’s opinion, notes to the financial statements, etc., which indicates this is the full quarterly financial report itself (not merely an announcement or summary). This matches the definition of an Interim/Quarterly Report (IR). Q1 2026
2026-05-14 Korean
타인에대한담보제공결정
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the decision to provide collateral to a third party, including specifics about the debtor, creditor, loan amount, collateral details, and board resolution date. It includes financial figures and references to regulatory compliance under the Capital Markets Act. The document is not a financial report, earnings release, or management discussion but a specific disclosure about a financing-related decision involving collateral provision. This fits the category of Capital/Financing Update (CAP), which covers updates on company financing activities or capital structure changes. The document length and content confirm it is not a brief announcement or a report publication notice but a substantive update on financing.
2026-05-06 Korean
소송등의판결ㆍ결정(일정금액이상의청구)
Legal Proceedings Report Classification · 97% confidence The text is a corporate announcement detailing the outcome of an ICC international arbitration case, including parties, case number, decision summary, financial impact, and next steps. This is a direct update on a legal proceeding rather than a financial report, so it falls under the Legal Proceedings Report category.
2026-04-15 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is the official announcement of the results of a Regular General Shareholders’ Meeting held on 2026-03-30, listing each agenda item and the voting outcomes with percentages. This matches the ‘Declaration of Voting Results & Voting Rights Announcements’ category, which covers shareholder vote results for AGMs.
2026-03-30 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal 'Notice of General Meeting of Shareholders' (주주총회소집공고) issued by Genexine. It outlines the date, location, agenda items (such as articles of incorporation changes, director/auditor compensation, and stock option grants), and procedures for electronic voting. This document is a classic proxy statement used to inform shareholders of an upcoming meeting and solicit their votes, which falls under the 'Proxy Solicitation & Information Statement' category.
2026-03-11 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.